




RealRate

PHARMACEUTICAL 2015

Biomarin Pharmaceutical INC
Rank 129 of 274

B:OMARIN®



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Biomarin Pharmaceutical INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biomarin Pharmaceutical INC compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 40% points. The greatest weakness of Biomarin Pharmaceutical INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 63% points.

The company's Economic Capital Ratio, given in the ranking table, is 293%, being 39% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	1,425,629
Cost of Goods Sold	129,764
Intangible Assets	210,836
Liabilities, Current	235,739
Liabilities, Non-Current	30,077
Other Assets	330,472
Other Compr. Net Income	22,448
Other Expenses	-3,115
Other Liabilities	696,743
Other Net Income	5,339
Other Revenues	751,040
Property and Equipment	523,516
Research and Development	461,543
Selling, General and Administrative Expense	302,156

Output Variable	Value in 1000 USD
Assets	2,490,453
Liabilities	962,559
Expenses	890,348
Revenues	751,040
Stockholders Equity	1,527,894
Net Income	-133,969
Comprehensive Net Income	-122,745
BaseVar	2,561,094
ECR before LimitedLiability	186%
Economic Capital Ratio	293%